Phosphorylated full‐length Tau interacts with 14‐3‐3 proteins via two short phosphorylated sequences, each occupying a binding groove of 14‐3‐3 dimer
Pharmacological modulation of the 14‐3‐3/Tau interaction has interest in drug discovery projects related to Alzheimer’s disease mitigation. Biophysical methods were used to define the interface, stoichiometry, and affinity characterizing the binding of 14‐3‐3 to full‐length phosphorylated Tau protei...
Gespeichert in:
Veröffentlicht in: | The FEBS journal 2021-03, Vol.288 (6), p.1918-1934 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1934 |
---|---|
container_issue | 6 |
container_start_page | 1918 |
container_title | The FEBS journal |
container_volume | 288 |
creator | Neves, João Filipe Petrvalská, Olivia Bosica, Francesco Cantrelle, François‐Xavier Merzougui, Hamida O'Mahony, Gavin Hanoulle, Xavier Obšil, Tomáš Landrieu, Isabelle |
description | Pharmacological modulation of the 14‐3‐3/Tau interaction has interest in drug discovery projects related to Alzheimer’s disease mitigation. Biophysical methods were used to define the interface, stoichiometry, and affinity characterizing the binding of 14‐3‐3 to full‐length phosphorylated Tau protein. We concluded that the small binding interface and the interaction of moderate affinity make the interface likely druggable for inhibition.
Protein–protein interactions (PPIs) remain poorly explored targets for the treatment of Alzheimer’s disease. The interaction of 14‐3‐3 proteins with Tau was shown to be linked to Tau pathology. This PPI is therefore seen as a potential target for Alzheimer’s disease. When Tau is phosphorylated by PKA (Tau‐PKA), several phosphorylation sites are generated, including two known 14‐3‐3 binding sites, surrounding the phosphorylated serines 214 and 324 of Tau. The crystal structures of 14‐3‐3 in complex with peptides surrounding these Tau phosphosites show that both these motifs are anchored in the amphipathic binding groove of 14‐3‐3. However, in the absence of structural data with the full‐length Tau protein, the stoichiometry of the complex or the interface and affinity of the partners is still unclear. In this work, we addressed these points, using a broad range of biophysical techniques. The interaction of the long and disordered Tau‐PKA protein with 14‐3‐3σ is restricted to two short sequences, containing phosphorylated serines, which bind in the amphipathic binding groove of 14‐3‐3σ. Phosphorylation of Tau is fundamental for the formation of this stable complex, and the affinity of the Tau‐PKA/14‐3‐3σ interaction is in the 1–10 micromolar range. Each monomer of the 14‐3‐3σ dimer binds one of two different phosphorylated peptides of Tau‐PKA, suggesting a 14‐3‐3/Tau‐PKA stoichiometry of 2 : 1, confirmed by analytical ultracentrifugation. These results contribute to a better understanding of this PPI and provide useful insights for drug discovery projects aiming at the modulation of this interaction. |
doi_str_mv | 10.1111/febs.15574 |
format | Article |
fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_02989190v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2501868358</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4274-b267dd92a3e9f7698bc89044b8ca0a61257f262915625433f1e87d74e5004ed03</originalsourceid><addsrcrecordid>eNqNkd-K1DAUxoso7rp64wNIwCv_zJqkSZNcrsOuKwwouIJ3IW1Pp1k6TTdJZ5g7H8E38N18ElM7DnojBkIOJ7_z8Z1zsuwpwecknTcNlOGccC7YveyUCEYXrODy_jFmX06yRyHcYpxzptTD7CSnSigq-Wn2_WPrwtA6v-9MhBo1Y9f9-Pqtg34dW3RjRmT7CN5UMaCdTSnC0nc-XTR4F8H2AW2tQXHnUEg6EQ1_Kwa4G6GvILxGYKoWuaoah73t18ig0vb1FK29c1tArvlTvrYb8I-zB43pAjw5vGfZ56vLm-X1YvXh3fvlxWpRMSrYoqSFqGtFTQ6qEYWSZSUVZqyUlcGmIJSLhhZUEV5QzvK8ISBFLRhwjBnUOD_LXsy6ren04O3G-L12xurri5WecpgqqYjCW5LY5zObBpB6C1HfutH3yZ6mHBNZyJzLRL2cqcq7EDw0R1mC9bQ3Pe1N_9pbgp8dJMdyA_UR_b2oBLyagR2UrgmVnUZ6xDDGXKgci9QOxpND-f_00kYTreuXbuxjKiWHUtvB_h-e9dXl20-z-59qL8f1</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2501868358</pqid></control><display><type>article</type><title>Phosphorylated full‐length Tau interacts with 14‐3‐3 proteins via two short phosphorylated sequences, each occupying a binding groove of 14‐3‐3 dimer</title><source>Access via Wiley Online Library</source><source>Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>Wiley Online Library (Open Access Collection)</source><source>Free Full-Text Journals in Chemistry</source><creator>Neves, João Filipe ; Petrvalská, Olivia ; Bosica, Francesco ; Cantrelle, François‐Xavier ; Merzougui, Hamida ; O'Mahony, Gavin ; Hanoulle, Xavier ; Obšil, Tomáš ; Landrieu, Isabelle</creator><creatorcontrib>Neves, João Filipe ; Petrvalská, Olivia ; Bosica, Francesco ; Cantrelle, François‐Xavier ; Merzougui, Hamida ; O'Mahony, Gavin ; Hanoulle, Xavier ; Obšil, Tomáš ; Landrieu, Isabelle</creatorcontrib><description>Pharmacological modulation of the 14‐3‐3/Tau interaction has interest in drug discovery projects related to Alzheimer’s disease mitigation. Biophysical methods were used to define the interface, stoichiometry, and affinity characterizing the binding of 14‐3‐3 to full‐length phosphorylated Tau protein. We concluded that the small binding interface and the interaction of moderate affinity make the interface likely druggable for inhibition.
Protein–protein interactions (PPIs) remain poorly explored targets for the treatment of Alzheimer’s disease. The interaction of 14‐3‐3 proteins with Tau was shown to be linked to Tau pathology. This PPI is therefore seen as a potential target for Alzheimer’s disease. When Tau is phosphorylated by PKA (Tau‐PKA), several phosphorylation sites are generated, including two known 14‐3‐3 binding sites, surrounding the phosphorylated serines 214 and 324 of Tau. The crystal structures of 14‐3‐3 in complex with peptides surrounding these Tau phosphosites show that both these motifs are anchored in the amphipathic binding groove of 14‐3‐3. However, in the absence of structural data with the full‐length Tau protein, the stoichiometry of the complex or the interface and affinity of the partners is still unclear. In this work, we addressed these points, using a broad range of biophysical techniques. The interaction of the long and disordered Tau‐PKA protein with 14‐3‐3σ is restricted to two short sequences, containing phosphorylated serines, which bind in the amphipathic binding groove of 14‐3‐3σ. Phosphorylation of Tau is fundamental for the formation of this stable complex, and the affinity of the Tau‐PKA/14‐3‐3σ interaction is in the 1–10 micromolar range. Each monomer of the 14‐3‐3σ dimer binds one of two different phosphorylated peptides of Tau‐PKA, suggesting a 14‐3‐3/Tau‐PKA stoichiometry of 2 : 1, confirmed by analytical ultracentrifugation. These results contribute to a better understanding of this PPI and provide useful insights for drug discovery projects aiming at the modulation of this interaction.</description><identifier>ISSN: 1742-464X</identifier><identifier>EISSN: 1742-4658</identifier><identifier>DOI: 10.1111/febs.15574</identifier><identifier>PMID: 32979285</identifier><language>eng</language><publisher>HOBOKEN: Wiley</publisher><subject>14‐3‐3 proteins ; Affinity ; Alzheimer's disease ; analytical ultracentrifugation ; Binding sites ; Biochemistry ; Biochemistry & Molecular Biology ; Crystal structure ; Dimers ; Grooves ; Kinases ; Life Sciences ; Life Sciences & Biomedicine ; Medical treatment ; Neurodegenerative diseases ; NMR spectroscopy ; Peptides ; Phosphorylation ; Protein interaction ; Proteins ; protein–protein interactions ; Science & Technology ; Stoichiometry ; Structural Biology ; Tau protein ; Ultracentrifugation</subject><ispartof>The FEBS journal, 2021-03, Vol.288 (6), p.1918-1934</ispartof><rights>2020 Federation of European Biochemical Societies</rights><rights>2020 Federation of European Biochemical Societies.</rights><rights>Copyright © 2021 Federation of European Biochemical Societies</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>13</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000579307500001</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c4274-b267dd92a3e9f7698bc89044b8ca0a61257f262915625433f1e87d74e5004ed03</citedby><cites>FETCH-LOGICAL-c4274-b267dd92a3e9f7698bc89044b8ca0a61257f262915625433f1e87d74e5004ed03</cites><orcidid>0000-0003-0582-1193 ; 0000-0003-4602-1272 ; 0000-0001-5944-1271 ; 0000-0002-3755-2680 ; 0000-0002-4883-2637 ; 0000-0002-0397-6477 ; 0000-0002-9855-1913</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Ffebs.15574$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Ffebs.15574$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,315,781,785,886,1418,1434,27929,27930,39263,45579,45580,46414,46838</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32979285$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-02989190$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Neves, João Filipe</creatorcontrib><creatorcontrib>Petrvalská, Olivia</creatorcontrib><creatorcontrib>Bosica, Francesco</creatorcontrib><creatorcontrib>Cantrelle, François‐Xavier</creatorcontrib><creatorcontrib>Merzougui, Hamida</creatorcontrib><creatorcontrib>O'Mahony, Gavin</creatorcontrib><creatorcontrib>Hanoulle, Xavier</creatorcontrib><creatorcontrib>Obšil, Tomáš</creatorcontrib><creatorcontrib>Landrieu, Isabelle</creatorcontrib><title>Phosphorylated full‐length Tau interacts with 14‐3‐3 proteins via two short phosphorylated sequences, each occupying a binding groove of 14‐3‐3 dimer</title><title>The FEBS journal</title><addtitle>FEBS J</addtitle><addtitle>FEBS J</addtitle><description>Pharmacological modulation of the 14‐3‐3/Tau interaction has interest in drug discovery projects related to Alzheimer’s disease mitigation. Biophysical methods were used to define the interface, stoichiometry, and affinity characterizing the binding of 14‐3‐3 to full‐length phosphorylated Tau protein. We concluded that the small binding interface and the interaction of moderate affinity make the interface likely druggable for inhibition.
Protein–protein interactions (PPIs) remain poorly explored targets for the treatment of Alzheimer’s disease. The interaction of 14‐3‐3 proteins with Tau was shown to be linked to Tau pathology. This PPI is therefore seen as a potential target for Alzheimer’s disease. When Tau is phosphorylated by PKA (Tau‐PKA), several phosphorylation sites are generated, including two known 14‐3‐3 binding sites, surrounding the phosphorylated serines 214 and 324 of Tau. The crystal structures of 14‐3‐3 in complex with peptides surrounding these Tau phosphosites show that both these motifs are anchored in the amphipathic binding groove of 14‐3‐3. However, in the absence of structural data with the full‐length Tau protein, the stoichiometry of the complex or the interface and affinity of the partners is still unclear. In this work, we addressed these points, using a broad range of biophysical techniques. The interaction of the long and disordered Tau‐PKA protein with 14‐3‐3σ is restricted to two short sequences, containing phosphorylated serines, which bind in the amphipathic binding groove of 14‐3‐3σ. Phosphorylation of Tau is fundamental for the formation of this stable complex, and the affinity of the Tau‐PKA/14‐3‐3σ interaction is in the 1–10 micromolar range. Each monomer of the 14‐3‐3σ dimer binds one of two different phosphorylated peptides of Tau‐PKA, suggesting a 14‐3‐3/Tau‐PKA stoichiometry of 2 : 1, confirmed by analytical ultracentrifugation. These results contribute to a better understanding of this PPI and provide useful insights for drug discovery projects aiming at the modulation of this interaction.</description><subject>14‐3‐3 proteins</subject><subject>Affinity</subject><subject>Alzheimer's disease</subject><subject>analytical ultracentrifugation</subject><subject>Binding sites</subject><subject>Biochemistry</subject><subject>Biochemistry & Molecular Biology</subject><subject>Crystal structure</subject><subject>Dimers</subject><subject>Grooves</subject><subject>Kinases</subject><subject>Life Sciences</subject><subject>Life Sciences & Biomedicine</subject><subject>Medical treatment</subject><subject>Neurodegenerative diseases</subject><subject>NMR spectroscopy</subject><subject>Peptides</subject><subject>Phosphorylation</subject><subject>Protein interaction</subject><subject>Proteins</subject><subject>protein–protein interactions</subject><subject>Science & Technology</subject><subject>Stoichiometry</subject><subject>Structural Biology</subject><subject>Tau protein</subject><subject>Ultracentrifugation</subject><issn>1742-464X</issn><issn>1742-4658</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>HGBXW</sourceid><recordid>eNqNkd-K1DAUxoso7rp64wNIwCv_zJqkSZNcrsOuKwwouIJ3IW1Pp1k6TTdJZ5g7H8E38N18ElM7DnojBkIOJ7_z8Z1zsuwpwecknTcNlOGccC7YveyUCEYXrODy_jFmX06yRyHcYpxzptTD7CSnSigq-Wn2_WPrwtA6v-9MhBo1Y9f9-Pqtg34dW3RjRmT7CN5UMaCdTSnC0nc-XTR4F8H2AW2tQXHnUEg6EQ1_Kwa4G6GvILxGYKoWuaoah73t18ig0vb1FK29c1tArvlTvrYb8I-zB43pAjw5vGfZ56vLm-X1YvXh3fvlxWpRMSrYoqSFqGtFTQ6qEYWSZSUVZqyUlcGmIJSLhhZUEV5QzvK8ISBFLRhwjBnUOD_LXsy6ren04O3G-L12xurri5WecpgqqYjCW5LY5zObBpB6C1HfutH3yZ6mHBNZyJzLRL2cqcq7EDw0R1mC9bQ3Pe1N_9pbgp8dJMdyA_UR_b2oBLyagR2UrgmVnUZ6xDDGXKgci9QOxpND-f_00kYTreuXbuxjKiWHUtvB_h-e9dXl20-z-59qL8f1</recordid><startdate>202103</startdate><enddate>202103</enddate><creator>Neves, João Filipe</creator><creator>Petrvalská, Olivia</creator><creator>Bosica, Francesco</creator><creator>Cantrelle, François‐Xavier</creator><creator>Merzougui, Hamida</creator><creator>O'Mahony, Gavin</creator><creator>Hanoulle, Xavier</creator><creator>Obšil, Tomáš</creator><creator>Landrieu, Isabelle</creator><general>Wiley</general><general>Blackwell Publishing Ltd</general><scope>BLEPL</scope><scope>DTL</scope><scope>HGBXW</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>7TM</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>1XC</scope><scope>VOOES</scope><orcidid>https://orcid.org/0000-0003-0582-1193</orcidid><orcidid>https://orcid.org/0000-0003-4602-1272</orcidid><orcidid>https://orcid.org/0000-0001-5944-1271</orcidid><orcidid>https://orcid.org/0000-0002-3755-2680</orcidid><orcidid>https://orcid.org/0000-0002-4883-2637</orcidid><orcidid>https://orcid.org/0000-0002-0397-6477</orcidid><orcidid>https://orcid.org/0000-0002-9855-1913</orcidid></search><sort><creationdate>202103</creationdate><title>Phosphorylated full‐length Tau interacts with 14‐3‐3 proteins via two short phosphorylated sequences, each occupying a binding groove of 14‐3‐3 dimer</title><author>Neves, João Filipe ; Petrvalská, Olivia ; Bosica, Francesco ; Cantrelle, François‐Xavier ; Merzougui, Hamida ; O'Mahony, Gavin ; Hanoulle, Xavier ; Obšil, Tomáš ; Landrieu, Isabelle</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4274-b267dd92a3e9f7698bc89044b8ca0a61257f262915625433f1e87d74e5004ed03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>14‐3‐3 proteins</topic><topic>Affinity</topic><topic>Alzheimer's disease</topic><topic>analytical ultracentrifugation</topic><topic>Binding sites</topic><topic>Biochemistry</topic><topic>Biochemistry & Molecular Biology</topic><topic>Crystal structure</topic><topic>Dimers</topic><topic>Grooves</topic><topic>Kinases</topic><topic>Life Sciences</topic><topic>Life Sciences & Biomedicine</topic><topic>Medical treatment</topic><topic>Neurodegenerative diseases</topic><topic>NMR spectroscopy</topic><topic>Peptides</topic><topic>Phosphorylation</topic><topic>Protein interaction</topic><topic>Proteins</topic><topic>protein–protein interactions</topic><topic>Science & Technology</topic><topic>Stoichiometry</topic><topic>Structural Biology</topic><topic>Tau protein</topic><topic>Ultracentrifugation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Neves, João Filipe</creatorcontrib><creatorcontrib>Petrvalská, Olivia</creatorcontrib><creatorcontrib>Bosica, Francesco</creatorcontrib><creatorcontrib>Cantrelle, François‐Xavier</creatorcontrib><creatorcontrib>Merzougui, Hamida</creatorcontrib><creatorcontrib>O'Mahony, Gavin</creatorcontrib><creatorcontrib>Hanoulle, Xavier</creatorcontrib><creatorcontrib>Obšil, Tomáš</creatorcontrib><creatorcontrib>Landrieu, Isabelle</creatorcontrib><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>The FEBS journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Neves, João Filipe</au><au>Petrvalská, Olivia</au><au>Bosica, Francesco</au><au>Cantrelle, François‐Xavier</au><au>Merzougui, Hamida</au><au>O'Mahony, Gavin</au><au>Hanoulle, Xavier</au><au>Obšil, Tomáš</au><au>Landrieu, Isabelle</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phosphorylated full‐length Tau interacts with 14‐3‐3 proteins via two short phosphorylated sequences, each occupying a binding groove of 14‐3‐3 dimer</atitle><jtitle>The FEBS journal</jtitle><stitle>FEBS J</stitle><addtitle>FEBS J</addtitle><date>2021-03</date><risdate>2021</risdate><volume>288</volume><issue>6</issue><spage>1918</spage><epage>1934</epage><pages>1918-1934</pages><issn>1742-464X</issn><eissn>1742-4658</eissn><abstract>Pharmacological modulation of the 14‐3‐3/Tau interaction has interest in drug discovery projects related to Alzheimer’s disease mitigation. Biophysical methods were used to define the interface, stoichiometry, and affinity characterizing the binding of 14‐3‐3 to full‐length phosphorylated Tau protein. We concluded that the small binding interface and the interaction of moderate affinity make the interface likely druggable for inhibition.
Protein–protein interactions (PPIs) remain poorly explored targets for the treatment of Alzheimer’s disease. The interaction of 14‐3‐3 proteins with Tau was shown to be linked to Tau pathology. This PPI is therefore seen as a potential target for Alzheimer’s disease. When Tau is phosphorylated by PKA (Tau‐PKA), several phosphorylation sites are generated, including two known 14‐3‐3 binding sites, surrounding the phosphorylated serines 214 and 324 of Tau. The crystal structures of 14‐3‐3 in complex with peptides surrounding these Tau phosphosites show that both these motifs are anchored in the amphipathic binding groove of 14‐3‐3. However, in the absence of structural data with the full‐length Tau protein, the stoichiometry of the complex or the interface and affinity of the partners is still unclear. In this work, we addressed these points, using a broad range of biophysical techniques. The interaction of the long and disordered Tau‐PKA protein with 14‐3‐3σ is restricted to two short sequences, containing phosphorylated serines, which bind in the amphipathic binding groove of 14‐3‐3σ. Phosphorylation of Tau is fundamental for the formation of this stable complex, and the affinity of the Tau‐PKA/14‐3‐3σ interaction is in the 1–10 micromolar range. Each monomer of the 14‐3‐3σ dimer binds one of two different phosphorylated peptides of Tau‐PKA, suggesting a 14‐3‐3/Tau‐PKA stoichiometry of 2 : 1, confirmed by analytical ultracentrifugation. These results contribute to a better understanding of this PPI and provide useful insights for drug discovery projects aiming at the modulation of this interaction.</abstract><cop>HOBOKEN</cop><pub>Wiley</pub><pmid>32979285</pmid><doi>10.1111/febs.15574</doi><tpages>17</tpages><orcidid>https://orcid.org/0000-0003-0582-1193</orcidid><orcidid>https://orcid.org/0000-0003-4602-1272</orcidid><orcidid>https://orcid.org/0000-0001-5944-1271</orcidid><orcidid>https://orcid.org/0000-0002-3755-2680</orcidid><orcidid>https://orcid.org/0000-0002-4883-2637</orcidid><orcidid>https://orcid.org/0000-0002-0397-6477</orcidid><orcidid>https://orcid.org/0000-0002-9855-1913</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1742-464X |
ispartof | The FEBS journal, 2021-03, Vol.288 (6), p.1918-1934 |
issn | 1742-464X 1742-4658 |
language | eng |
recordid | cdi_hal_primary_oai_HAL_hal_02989190v1 |
source | Access via Wiley Online Library; Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; Wiley Online Library (Open Access Collection); Free Full-Text Journals in Chemistry |
subjects | 14‐3‐3 proteins Affinity Alzheimer's disease analytical ultracentrifugation Binding sites Biochemistry Biochemistry & Molecular Biology Crystal structure Dimers Grooves Kinases Life Sciences Life Sciences & Biomedicine Medical treatment Neurodegenerative diseases NMR spectroscopy Peptides Phosphorylation Protein interaction Proteins protein–protein interactions Science & Technology Stoichiometry Structural Biology Tau protein Ultracentrifugation |
title | Phosphorylated full‐length Tau interacts with 14‐3‐3 proteins via two short phosphorylated sequences, each occupying a binding groove of 14‐3‐3 dimer |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T14%3A21%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phosphorylated%20full%E2%80%90length%20Tau%20interacts%20with%2014%E2%80%903%E2%80%903%20proteins%20via%20two%20short%20phosphorylated%20sequences,%20each%20occupying%20a%20binding%20groove%20of%2014%E2%80%903%E2%80%903%20dimer&rft.jtitle=The%20FEBS%20journal&rft.au=Neves,%20Jo%C3%A3o%20Filipe&rft.date=2021-03&rft.volume=288&rft.issue=6&rft.spage=1918&rft.epage=1934&rft.pages=1918-1934&rft.issn=1742-464X&rft.eissn=1742-4658&rft_id=info:doi/10.1111/febs.15574&rft_dat=%3Cproquest_hal_p%3E2501868358%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2501868358&rft_id=info:pmid/32979285&rfr_iscdi=true |